Scarica l'app Stockscreener
13.48
6.65%
-0.96
Dopo l'orario di chiusura:
13.50
0.02
+0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$14.44
Aprire:
$13.98
Volume 24 ore:
983.56K
Relative Volume:
1.03
Capitalizzazione di mercato:
$1.26B
Reddito:
$288.00K
Utile/perdita netta:
$-228.06M
Rapporto P/E:
-3.1718
EPS:
-4.25
Flusso di cassa netto:
$-168.82M
1 W Prestazione:
-12.81%
1M Prestazione:
-13.20%
6M Prestazione:
-40.75%
1 anno Prestazione:
-23.02%
Intervallo 1D:
$13.23
$13.98
Intervallo di 1 settimana:
$13.23
$15.44
Portata 52W:
$11.40
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta VRDN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
13.48 | 1.26B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Iniziato | TD Cowen | Buy |
| 2024-09-11 | Reiterato | Needham | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-05-09 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Iniziato | BTIG Research | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-17 | Iniziato | Wells Fargo | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2022-12-19 | Iniziato | Cowen | Outperform |
| 2022-12-19 | Iniziato | Needham | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-12-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-11-18 | Iniziato | SVB Leerink | Outperform |
| 2021-10-12 | Iniziato | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Quantbot Technologies LP Invests $164,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Swiss National Bank - Defense World
Raymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Where are the Opportunities in (VRDN) - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
AlphaQuest LLC Acquires 1,519 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Commit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using Options - Nasdaq
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon Corp - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Arizona State Retirement System - Defense World
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc. - Defense World
Viridian Therapeutics at Leerink’s Conference: Progress in TED Treatments By Investing.com - Investing.com UK
Viridian Therapeutics appoints new director, sees board resignation By Investing.com - Investing.com South Africa
Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq
Viridian Therapeutics appoints new director, sees board resignation - Investing.com India
What is B. Riley’s Forecast for VRDN Q1 Earnings? - Defense World
Principal Financial Group Inc. Has $3.42 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
What is B. Riley’s Estimate for VRDN Q2 Earnings? - Defense World
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus.com
Viridian Therapeutics inks new $300M sales agreement By Investing.com - Investing.com South Africa
Viridian Therapeutics Terminates Prior $175 Million Sale Agreement -March 04, 2025 at 06:36 am EST - Marketscreener.com
Viridian Therapeutics Enters New $300M Sale Agreement - TipRanks
Viridian Therapeutics inks new $300M sales agreement - Investing.com
Rhumbline Advisers Has $1.92 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges - TipRanks
Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView
Q1 EPS Estimates for Viridian Therapeutics Raised by Wedbush - Defense World
How to Take Advantage of moves in (VRDN) - Stock Traders Daily
Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window - Seeking Alpha
FY2027 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World
Viridian Therapeutics (NASDAQ:VRDN) Posts Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat
RBC Capital Adjusts Viridian Therapeutics Price Target to $46 From $47, Maintains OutperformSpeculative Risk Rating - Marketscreener.com
Viridian Therapeutics: Promising Market Position and Growth Prospects Justify Buy Rating - TipRanks
Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
Viridian Therapeutics Reports Strong Progress and Financials - TipRanks
Viridian Therapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Viridian Therapeutics reports Q4 EPS (81c), consensus ($1.04) - TipRanks
Viridian Therapeutics Positioned for Market Leadership with Strategic Advancements and Competitive Edge - TipRanks
Viridian Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VRDNViridian Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Viridian Therapeutics: Strong TED Trial Results and Promising Pipeline Drive Buy Rating - TipRanks
Viridian Therapeutics' Q4 Net Loss Narrows, Revenue Flat -February 27, 2025 at 09:27 am EST - Marketscreener.com
Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Revenue $72,000 -February 27, 2025 at 07:20 am EST - Marketscreener.com
Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $1.05 Loss - Marketscreener.com
Viridian Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
Viridian Therapeutics Becomes Oversold (VRDN) - Nasdaq
Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Tuesday - Defense World
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70 - MarketBeat
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):